Eric Van Cutsem, MD, PhD, of University Hospitals Gasthuisberg/Leuven, Leuven, Belgium, discusses the use of trastuzumab for the treatment of advanced HER2-positive gastric cancer.

Trastuzumab is utilized as a targeted therapy for both gastric cancer and breast cancer, but gastric cancer has its own unique set of challenges, says Van Cutsem.

While toxicity is not as much of an issue with trastuzumab for gastric cancer as it is for breast cancer, survival is shorter. Resistance is also a challenge, says Van Cutsem, and efforts need to be made to better understand the mechanisms behind it.   

View more from the 2015 GI Cancer Symposium

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Gastrointestinal Cancer

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Gastrointestinal Cancers Symposium (ASCO GI)

Eric Van Cutsem, MD, PhD of University Hospitals Gasthuisberg/Leuven, Leuven, Belgium, discusses the use of trastuzumab for the treatment of advanced HER2-positive gastric cancer.

Dr. Cutsem on Challenges of Targeted Therapies in Gastric Cancer